Non-Tumor Cells within the Tumor Microenvironment—The “Eminence Grise” of the Glioblastoma Pathogenesis and Potential Targets for Therapy
Aleksandra S. Bugakova,
Daria A. Chudakova,
Maria S. Myzina,
Elvira P. Yanysheva,
Iuliia V. Ozerskaya,
Alesya V. Soboleva,
Vladimir P. Baklaushev,
Gaukhar M. Yusubalieva
Affiliations
Aleksandra S. Bugakova
Federal Center for Brain and Neurotechnologies, Federal Medical and Biological Agency of Russia, 117513 Moscow, Russia
Daria A. Chudakova
Federal Center for Brain and Neurotechnologies, Federal Medical and Biological Agency of Russia, 117513 Moscow, Russia
Maria S. Myzina
Federal Center for Brain and Neurotechnologies, Federal Medical and Biological Agency of Russia, 117513 Moscow, Russia
Elvira P. Yanysheva
Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies Federal Medical and Biological Agency of Russia, 115682 Moscow, Russia
Iuliia V. Ozerskaya
Pulmonology Research Institute, Federal Medical and Biological Agency of Russia, 115682 Moscow, Russia
Alesya V. Soboleva
Federal Center for Brain and Neurotechnologies, Federal Medical and Biological Agency of Russia, 117513 Moscow, Russia
Vladimir P. Baklaushev
Federal Center for Brain and Neurotechnologies, Federal Medical and Biological Agency of Russia, 117513 Moscow, Russia
Gaukhar M. Yusubalieva
Federal Center for Brain and Neurotechnologies, Federal Medical and Biological Agency of Russia, 117513 Moscow, Russia
Glioblastoma (GBM) is the most common malignancy of the central nervous system in adults. GBM has high levels of therapy failure and its prognosis is usually dismal. The phenotypic heterogeneity of the tumor cells, dynamic complexity of non-tumor cell populations within the GBM tumor microenvironment (TME), and their bi-directional cross-talk contribute to the challenges of current therapeutic approaches. Herein, we discuss the etiology of GBM, and describe several major types of non-tumor cells within its TME, their impact on GBM pathogenesis, and molecular mechanisms of such an impact. We also discuss their value as potential therapeutic targets or prognostic biomarkers, with reference to the most recent works on this subject. We conclude that unless all “key player” populations of non-tumor cells within the TME are considered, no breakthrough in developing treatment for GBM can be achieved.